Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $9.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 12.53% from the stock’s current price.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
NBRV has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Nabriva Therapeutics AG in a research report on Friday, June 23rd. SunTrust Banks, Inc. assumed coverage on shares of Nabriva Therapeutics AG in a research report on Friday, August 25th. They issued a “buy” rating and a $20.00 target price on the stock. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective (up from $15.00) on shares of Nabriva Therapeutics AG in a research report on Tuesday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.78.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 8.22 on Wednesday. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $14.10. The stock’s market capitalization is $220.61 million. The stock’s 50 day moving average is $8.44 and its 200-day moving average is $9.84.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. On average, equities research analysts predict that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Nabriva Therapeutics AG (NBRV) Upgraded to “Buy” by Zacks Investment Research” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/10/11/nabriva-therapeutics-ag-nbrv-upgraded-to-buy-by-zacks-investment-research.html.
In other news, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the firm’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $10.51, for a total value of $734,165.54. Following the completion of the sale, the insider now owns 2,490,952 shares in the company, valued at approximately $26,179,905.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of Nabriva Therapeutics AG stock in a transaction dated Monday, September 18th. The stock was purchased at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 57,219 shares of company stock worth $535,919 and have sold 252,845 shares worth $2,585,694. Company insiders own 2.75% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors lifted its stake in shares of Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after acquiring an additional 7,924 shares during the period. Royal Bank of Canada lifted its stake in shares of Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 8,650 shares during the period. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG in the 1st quarter worth $1,870,000. Finally, Wellington Management Group LLP lifted its stake in shares of Nabriva Therapeutics AG by 9.9% in the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after acquiring an additional 193,951 shares during the period. Institutional investors own 50.23% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.